Recent Finacing
Recent Raise
ImmuVen develops soluble T-cell receptor biotherapeutics using a proprietary platform to select and optimize high‑affinity soluble TCRs, advancing IMV0123 to neutralize Staphylococcus aureus superantigens.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor